| Gene symbol | gag | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001802.1 (336..1838) | dbXrefs | |
| Description | Pr55(Gag) | ||||
| Gene symbol | env | Synonyms | None | Type of gene | protein coding |
| Chromosome | - | Map location | NC_001802.1 (5771..8341) | dbXrefs | |
| Description | Envelope surface glycoprotein gp160, precursor | ||||
| Gene symbol | IL12A | Synonyms | CLMF, IL-12A, NFSK, NKSF1, P35 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q25.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | interleukin 12A | ||||
| Gene symbol | IL12B | Synonyms | CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2 | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q33.3 | dbXrefs | |
| Description | interleukin 12B | ||||
| GTO ID | GTC1277 |
| Trial ID | NCT00517569 |
| Disease | HIV Infection |
| Altered gene | gag|env|IL-12A|IL-12B |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | GX-12 |
| Co-treatment | Highly active antiretroviral therapy(HAART) |
| Phase | Phase1 |
| Recruitment status | Unknown |
| Title | Phase I Study for Assessment of Safety of Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients |
| Year | 2007 |
| Country | Korea,Republic of |
| Company sponsor | Genexine, Inc. |
| Other ID(s) | GX-12_HIV_I |
| Vector information | |||||
|
|||||
| Cohort1: dose level 1 | |||||||||
|
|||||||||
| Cohort2: dose level 2 | |||||||||
|
|||||||||
| Cohort3: dose level 3 | |||||||||
|
|||||||||